Neoadjuvant chemotherapy for resectable adenocarcinoma of the panctreatic head - a prospective phase II trial

被引：0
|
作者：
Pestalozzi, B. C. [1 ]
Heinrich, S. [1 ]
Schafer, M. [1 ]
Pierre-Alain, C. [1 ]
机构：
[1] Univ Hosp Zurich, Zurich, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4610
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prospective phase II trial of Neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head
    Heinrich, Stefan
    Pestalozzi, Bernhard C.
    Schaefer, Markus
    Weber, Achim
    Bauerfeind, Peter
    Knuth, Alexander
    Clavien, Pierre-Alain
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2526 - 2531
  • [2] Neoadjuvant genicitabine/cisplatin for resectable adenocarcinoma of the pancreatic head-a prospective phase I trial
    Heinrich, S.
    Pestalozzi, B.
    Schafer, M.
    Hany, T.
    Bauerfeind, P.
    Perren, A.
    Knuth, A.
    Clavien, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: A prospective, multi-institutional, phase II trial
    Mizuma, Masamichi
    Motoi, Fuyuhiko
    Ishida, Kazuyuki
    Fujishima, Fumiyoshi
    Ottomo, Shigeru
    Oikawa, Masaya
    Okada, Takaho
    Shimamura, Hiromune
    Takemura, Shinichi
    Ono, Fuminori
    Akada, Masanori
    Nakagawa, Kei
    Katayose, Yu
    Egawa, Shinichi
    Unno, Michiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [4] A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Keiichi Okano
    Hironobu Suto
    Minoru Oshima
    Eri Maeda
    Naoki Yamamoto
    Keitaro Kakinoki
    Hideki Kamada
    Tsutomu Masaki
    Shigeo Takahashi
    Toru Shibata
    Yasuyuki Suzuki
    Annals of Surgical Oncology, 2017, 24 : 2777 - 2784
  • [5] A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Okano, Keiichi
    Suto, Hironobu
    Oshima, Minoru
    Maeda, Eri
    Yamamoto, Naoki
    Kakinoki, Keitaro
    Kamada, Hideki
    Masaki, Tsutomu
    Takahashi, Shigeo
    Shibata, Toru
    Suzuki, Yasuyuki
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (09) : 2777 - 2784
  • [6] A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma
    Al-Fakeeh, Ali
    Ferri, Lorenzo
    Mulla, Nasser
    Doerksen, Tonia
    Al-Ruzug, Ibrahim
    Santos, Fabiano
    Alcindor, Thierry
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [7] A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma
    Ali Al-Fakeeh
    Lorenzo Ferri
    Nasser Mulla
    Tonia Doerksen
    Ibrahim Al-Ruzug
    Fabiano Santos
    Thierry Alcindor
    Medical Oncology, 2016, 33
  • [8] A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.
    van den Ende, Tom
    de Clercq, Nicolien C.
    Henegouwen, Mark I. van Berge
    Gisbertz, Suzanne S.
    Meijer, Sybren L.
    Schokker, Sandor
    Bergman, Jacques J. G. H. M.
    Mohammad, Nadia Haj
    Ruurda, Jelle P.
    van Hillegersberg, Richard
    Mook, Stella
    Nieuwdorp, Max
    Soeratram, Tanya T. D.
    Ylstra, Bauke
    van Grieken, Nicole C. T.
    de Gruijl, Tanja D.
    Bijlsma, Maarten F.
    Hulshof, Maarten C. C. M.
    Van Laarhoven, Hanneke W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
    Davar, Diwakar
    Morrison, Robert M.
    Dzutsev, Amiran K.
    Karunamurthy, Arivarasan
    Chauvin, Joe-Marc
    Amatore, Florent
    Deutsch, Julie S.
    Das Neves, Rodrigo X.
    Rodrigues, Richard R.
    McCulloch, John A.
    Wang, Hong
    Hartman, Douglas J.
    Badger, Jonathan H.
    Fernandes, Miriam R.
    Bai, Yulong
    Sun, Jie
    Cole, Alicia M.
    Aggarwal, Poonam
    Fang, Jennifer R.
    Deitrick, Christopher
    Bao, Riyue
    Duvvuri, Umamaheswar
    Sridharan, Shaum S.
    Kim, Seungwon W.
    Choudry, Haroon A.
    Holtzman, Matthew P.
    Pingpank, James F.
    O'Toole, James Patrick
    DeBlasio, Richelle
    Jin, Yang
    Ding, Quanquan
    Gao, Wentao
    Groetsch, Christopher
    Pagliano, Ornella
    Rose, Amy
    Urban, Corey
    Singh, Jagjit
    Divarkar, Prajan
    Mauro, David
    Bobilev, Dmitri
    Wooldridge, James
    Krieg, Arthur M.
    Fury, Matthew G.
    Whiteaker, Jeffrey R.
    Zhao, Lei
    Paulovich, Amanda G.
    Najjar, Yana G.
    Luke, Jason J.
    Kirkwood, John M.
    Taube, Janis M.
    CANCER CELL, 2024, 42 (11) : 1898 - +
  • [10] Is Neoadjuvant Chemoradiotherapy Superior to Neoadjuvant Chemotherapy in Resectable Esophageal Adenocarcinoma?
    Prescott, A. T.
    Koshenkov, V. P.
    Koru-Sengul, T.
    Freiser, M. E.
    Rosati, C.
    Sparling, J. L.
    Allan, B. J.
    Franceschi, D.
    Livingstone, A.
    Avisar, E.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S108 - S108
12345